American Association for Cancer Research

SHERPA: Unknown

People

  1. Seidman
    Seidman
  2. Hudis
    Hudis
  3. Norton
    Norton
  4. D'Andrea-Carlino
    D'Andrea-Carlino
  5. Fornier
    Fornier
  6. Lake
    Lake
  7. Dang
    Dang
  8. Modi
    Modi
  9. Bromberg
    Bromberg
  10. Panageas
    Panageas

Groups

  1. Breast Medicine Service (33)
  2. Department of Medicine (33)
  3. Solid Tumor Oncology Division (33)
  4. Survivorship Research (19)
  5. Alan and Sandra Gerry Metastasis and Tumor Ecosystems Center (15)
  6. Epidemiology and Biostatistics (14)
  7. Biostatistics Service (12)
  8. Population Sciences Research Program (10)
  9. GSK Faculty (8)
  10. Psychiatry and Behavioral Sciences, Department of (8)
Search Within
  1. "Andrew Seidman"
Formats
  1. Meeting Abstract (23)
  2. Journal Article (10)
Groups
  1. Breast Medicine Service (33)
  2. Department of Medicine (33)
  3. Solid Tumor Oncology Division (33)
  4. Survivorship Research (19)
  5. Alan and Sandra Gerry Metastasis and Tumor Ecosystems Center (15)
  6. Epidemiology and Biostatistics (14)

More Groups

People
  1. Andrew Seidman (33)
  2. Clifford Hudis (17)
  3. Larry Norton (15)
  4. Gabriella D'Andrea-Carlino (10)
  5. Diana Lake (8)
  6. Maura Dickler (8)

More People

Years
  1. 2021 (1)
  2. 2020 (3)
  3. 2019 (4)
  4. 2018 (1)
  5. 2017 (2)
  6. 2016 (2)

More Years

Publications
  1. Cancer Research (23)
  2. Clinical Cancer Research (10)

Results (33)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Results from CONTESSA: A phase 3 study of tesetaxel plus a reduced dose of capecitabine versus capecitabine alone in patients with HER2-, hormone receptor + (HR+) metastatic breast cancer (MBC) who have previously received a taxane
    Meeting Abstract

    O'Shaughnessy, J.; Schwartzberg, L.; Piccart, M.; Rugo, H. S.; Yardley, D. A.; Cortes, J.; Untch, M.; Harbeck, N.; Wright, G. S.; Bondarenko, I.; more...
    Cancer Research (2021)

    Fulltext@MSK | Save
  • CONTESSA 2: A multinational, multicenter, phase 2 study of tesetaxel plus a reduced dose of capecitabine in patients with HER2-, HR+ metastatic breast cancer (MBC) who have not previously received a taxane
    Meeting Abstract

    Schwartzberg, L.; Asselah, J.; Bondarenko, I.; Chae, Y.; DaCosta, N.; Feng, Y. H.; Izarzugaza, Y.; Lemieux, J.; Liu, M. C.; Marx, G.; more...
    Cancer Research (2020)

    Fulltext@MSK | Save
  • CONTESSA: A multinational, multicenter, randomized, phase 3 registration study of tesetaxel plus a reduced dose of capecitabine in patients with HER2-, hormone receptor + (HR+) metastatic breast cancer (MBC) who have previously received a taxane
    Meeting Abstract

    O'Shaughnessy, J.; Piccart, M.; Schwartzberg, L.; Cortes, J.; Harbeck, N.; Im, S. A.; Rugo, H.; Untch, M.; Yardley, D.; Bondarenko, I.; more...
    Cancer Research (2020)

    Fulltext@MSK | Save
  • Initial real world treatment patterns and outcomes of abemaciclib for the treatment of HR+, HER2- metastatic breast cancer
    Meeting Abstract

    Carter, G. C.; Sheffield, K. M.; Gossai, A.; Huang, Y. J.; Zhu, Y. E.; Bowman, L.; Smith, E. N.; Mathur, R.; Cohen, A. B.; Baxi, S.; more...
    Cancer Research (2020)

    Fulltext@MSK | Save
  • Influence of prognostic factors on outcomes among metastatic breast cancer patients treated with CDK4&6 inhibitors in routine clinical practice
    Meeting Abstract

    Saverno, K. R.; Carter, G. C.; Li, L.; Battiato, L. A.; Huang, Y. J.; Smyth, E. N.; Price, G. L.; Sheffield, K. M.; Baxi, S. S.; Kuk, D.; more...
    Cancer Research (2019)

    Fulltext@MSK | Save
  • A phase I trial of sorafenib with whole brain radiotherapy (WBRT) in breast cancer patients with brain metastases and a correlative study of FLT-PET brain imaging in patients receiving WBRT with or without sorafenib
    Meeting Abstract

    Morikawa, A.; Jhaveri, K.; Grkovski, M.; Tang, K.; Humm, J. L.; Holodny, A.; Beal, K.; Schoder, H.; Seidman, A. D.
    Cancer Research (2019)

    Fulltext@MSK | Save
  • Chemotherapy-induced peripheral neuropathy in breast cancer survivors: Comparison of objective and subjective measures
    Meeting Abstract

    Bao, T.; Kwon, A.; Piulson, L.; Chen, P.; Li, Q.; Patil, S.; Seidman, A.; Blinder, V.; Vahdat, L.; Zhi, W. I.; more...
    Cancer Research (2019)

    Fulltext@MSK | Save
  • Phase I study of intermittent high-dose lapatinib alternating with capecitabine for HER2-positive breast cancer patients with central nervous system metastases
    Journal Article

    Morikawa, A.; de Stanchina, E.; Pentsova, E.; Kemeny, M. M.; Li, B. T.; Tang, K.; Patil, S.; Fleisher, M.; Van Poznak, C.; Norton, L.; more...
    Clinical Cancer Research (2019)

    Fulltext@MSK | Save
  • ATTAIN: Phase 3 study of etirinotecan pegol (EP) vs treatment of physician's choice (TPC) in patients (pts) with metastatic breast cancer (MBC) who have stable brain metastases (BM) previously treated with an anthracycline, a taxane, and capecitabine (ATC)
    Meeting Abstract

    Tripathy, D.; Sara, T.; Seidman, A. D.; Anders, C. K.; Ibrahim, N.; Rugo, H. S.; Twelves, C. J.; Diéras, V.; Müller, V.; Hannah, A.; more...
    Cancer Research (2018)

    Fulltext@MSK | Save
  • Phase 3 study of etirinotecan pegol versus treatment of physician's choice in patients with metastatic breast cancer who have stable brain metastases previously treated with an anthracycline, a taxane, and capecitabine
    Meeting Abstract

    Tripathy, D.; Tolaney, S.; Seidman, A. D.; Anders, C. K.; Ibrahim, N.; Rugo, H. S.; Twelves, C. J.; Cortes, J.
    Cancer Research (2017)

    Fulltext@MSK | Save

    • American Association for Cancer Research – authorized name for: